Biotech Startup Due Diligence at Series A Stage: Complete Investor Guide
Companies developing novel therapeutics, diagnostics, genomics tools, and biological technologies for human health and disease treatment. This guide focuses specifically on due diligence considerations at the Series A stage ($5M–$20M raise, $20M–$80M post-money).
Series A Stage at a Glance
The company has proven product-market fit and is raising to scale: hiring, marketing, and expanding to new customers or geographies.
Key Metrics for Biotech Startups at Series A
These are the 4 metrics that institutional investors evaluate for Biotech startups. DDR automatically extracts and benchmarks these from pitch deck data and OSINT sources.
Red Flags in Biotech Pitch Decks
DDR detects these 3 sector-specific red flags automatically when screening a Biotech startup pitch deck. Each flag is severity-weighted based on impact to investment thesis.
Due Diligence Focus Areas: Biotech
These are the priority investigation areas for Biotech startups that experienced investors always verify before committing capital.
- Scientific advisory board composition and engagement level
- Patent landscape: freedom-to-operate analysis and competitor IP
- Clinical trial design review with scientific expert
- Regulatory strategy: pre-IND meeting notes with FDA if available
- CMC (Chemistry, Manufacturing, and Controls) — manufacturing scalability
Key Questions to Ask the Founder
These founder interview questions surface the most common gaps and risks in Biotech startup pitches.
- What are the 3 biggest scientific risks in your program and what data would de-risk each one?
- What does success look like in Phase 2 — what endpoint are you powering for?
- Walk me through your IP strategy: what is the core patent and when does it expire?
- What is your clinical development cost and runway to the next major milestone?
Comparable Companies & Exits: Biotech
Regulatory & Compliance Risks
- FDA IND/NDA/BLA pathway: multiple review cycles, advisory committee meetings
- Clinical trial regulations: GCP compliance, IRB approval, informed consent
- Drug pricing scrutiny: IRA Medicare price negotiation for high-cost drugs
- EU EMA: separate approval pathway for European markets
OSINT Signals to Check
DDR automatically checks these 4 signals from public sources when analyzing a Biotech startup:
- ClinicalTrials.gov: registered study status and enrollment progress
- PubMed: peer-reviewed publications from founding team
- USPTO patent database: core composition-of-matter patents
- FDA warning letters database: any prior FDA actions
Biotech Due Diligence — All Guides
Screen Any Biotech Startup in 5 Minutes
Upload a pitch deck PDF and DDR automatically runs this full due diligence framework — 13 OSINT sources, founder verification, all sector-specific red flags, comparable company analysis, and INVEST/PASS verdict.
GET YOUR FREE SCAN →